Ann: FDA Letter Requires Patient Instruction Update, page-287

1. The loose fruit has been shaken from the tree
2. The market values BOT's potential and places a higher value on approval next year than it did this far out from approval in 2023.

Both points are incorrect

1. The daily trading volume post and pre FDA rejection suggests how the smart money started leaving 3 days before the FDA rejection and in large volumes post rejection. The share price as a result came down from the highs of 21.5 cents to 11.5 cents in a matter of days.

2. Market is not taking any notice at all. If it was as how you put it then the share price would have been sitting well above the 15 cents barrier and on volume. We have a number of price sensitive "positive" anns from the management since the FDA rejection and it has done nothing to move the needle.

10 cents is where this will be in coming day before the end of the year in my opinion.